Rankings
▼
Calendar
TARS Q3 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$119M
+146.7% YoY
Gross Profit
$94M
79.3% margin
Operating Income
-$15M
-12.2% margin
Net Income
-$13M
-10.6% margin
EPS (Diluted)
$-0.30
QoQ Revenue Growth
+15.6%
Cash Flow
Operating Cash Flow
$18M
Free Cash Flow
$16M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$535M
Total Liabilities
$199M
Stockholders' Equity
$335M
Cash & Equivalents
$113M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$119M
$48M
+146.7%
Gross Profit
$94M
$45M
+109.7%
Operating Income
-$15M
-$25M
+42.3%
Net Income
-$13M
-$23M
+46.3%
Revenue Segments
Product
$119M
100%
← FY 2025
All Quarters
Q4 2025 →